Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration

Sponsor
Centre Hospitalier Intercommunal Creteil
Study ID
NCT02157077
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis. The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval injection until week 26.

Key Dates

Start date
Dec 31, 2013
Status verified
Dec 2022
Primary completion
Dec 31, 2015
Completion
Dec 31, 2015

Study Design

Enrollment
90 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Aflibercept
    Patients will receive 2 mg of aflibercept by intravitreal injection every 4 weeks until week 8, followed by every 6 weeks to week 26

Primary Outcome Measure

Change from baseline in maximal height of pigment epithelium detachment (PED) at 12 weeks [ Time Frame: Baseline and 12 weeks ]

Related Studies